Michael J. Foster - Aug 31, 2022 Form 4 Insider Report for Sabra Health Care REIT, Inc. (SBRA)

Role: Director
Signature: /s/ Michael Costa, as Attorney-in-Fact
Stock symbol: SBRA
Transactions as of: Aug 31, 2022
Transactions value $: $0
Form type: 4
Date filed: 9/2/2022, 04:04 PM
Previous filing: Jun 16, 2022
Next filing: Dec 2, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SBRA	Common Stock	Award	$0	+768	+1.32%	$0.00	59K	Aug 31, 2022	Direct	F1, F2
holding	SBRA	Common Stock						42.5K	Aug 31, 2022	401(k) Plan

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate.
F2	Includes 7,439 unvested stock units and 31,684 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock.

Content

Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate.

Includes 7,439 unvested stock units and 31,684 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock.